Loading...
Loading...
Wedbush upgraded Ironwood Pharmaceuticals
IRWD from Underperform to Neutral and raised the price target from $11.00 to $13.00.
Wedbush said, "Early script data for Q1:13 (5 weeks) suggests strong week-over-week LINZESS performance (20,000+ pills per week growth), which, if sustained, would see Q1 and FY:13 end-user demand well ahead of our initial conservative estimates. We are adjusting sales and expense numbers and, as a consequence of our revised outlook, are removing our expectation that IRWD will require an additional $100M equity financing (although additional cash to bolster the balance sheet continues to be in our expectations)."
Ironwood Pharmaceuticals closed at $13.58 on Tuesday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in